Tumor location does not impact long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China.

Background: The seventh edition of the American Joint Committee on Cancer staging system considers tumor location as a factor in staging esophageal squamous cell carcinoma (ESCC). However, more data are essential to test its efficacy. The purpose of this study is to assess whether tumor location should be included as a factor in staging of thoracic ESCC in Chinese patients.

Modification of nodal categories in the seventh american joint committee on cancer staging system for esophageal squamous cell carcinoma in Chinese patients.

Background: More data are essential to test the efficacy of the American Joint Committee on Cancer (AJCC) system for staging esophageal squamous cell carcinoma. We tested the classifiers used in the AJCC staging system and propose a modification to this system to better represent the survival characteristics of esophageal squamous cell carcinoma in the Chinese population.

Methods: We used data from two centers, which established the training (n=1,006) and validation (n=783) cohorts.

Expression of G3BP and RhoC in esophageal squamous carcinoma and their effect on prognosis.

Aim: To investigate the expression and significance of G3BP and RhoC proteins in esophageal squamous carcinoma (ESC).

Methods: The expression of G3BP and Rhoc proteins in 80 cases of ESC was detected by immunohistochemistry. The relationship was studied between the expression of the two proteins and tumor size, differentiation degree, TNM stage, lymph node metastasis and prognosis of ESC.

[Expression of Ras-GTPase-activating protein SH 3 domain binding protein and osteopontin in esophageal squamous carcinoma and their effects on prognosis].

Objective: To investigate the expressions and significances of Ras-GTPase-activating protein SH 3 domain binding protein(G3BP) and osteopontin (OPN) proteins in esophageal squamous carcinoma (ESC).

Methods: The expressions of G3BP and OPN proteins in 80 cases of ESC were detected by immunohistochemistry. The relationships between the 2 protein expression and tumor size, differentiation degree, TNM stage, lymph node metastasis and prognosis of ESC were also explored.

[Expressions of RhoC and osteopontin in esophageal squamous carcinoma and association with the patients' prognosis].

Objective: To investigate the expressions of RhoC and osteopontin (OPN) protein in esophageal squamous carcinoma (ESC) and their association with the biological behavior of ESC.

Methods: The expressions of RhoC and OPN protein were detected in 80 ESC cases by immunohistochemistry.

Results: The positive expression rate of RhoC was 66.

[Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma].

Objective: To investigate the expressions of vascular endothelial growth factor-C (VEGF-C) and matrix metalloproteinases-2 (MMP-2) proteins and its relationship with the biological behaviors of non-small cell lung carcinoma (NSCLC).

Methods: Immunohistochemical staining was used to detect the expressions of VEGF-C and MMP-2 proteins in 42 cases of NSCLC tissues. The relationship of VEGF-C and MMP-2 expressions was analyzed with the tumor size, lymphatic vessel density (LVD), histological type, differentiation, clinical recurrence, lymph node metastasis and patients' survival time.

[Expression of vascular endothelial growth factor C and cyclooxygenase-2 in non-small-cell lung carcinoma and their clinical significance].

Objective: To investigate the expression of vascular endothelial growth factor-C (VEGF-C) and cyclooxygenase-2 (COX-2) proteins, and their relationship with biological behaviors of non-small-cell lung carcinoma (NSCLC).

Methods: Immunohistochemical staining was used to detect the expression of VEGF-C and COX-2 proteins in 77 cases of NSCLC. The relationship was analyzed between the expression of VEGF-C, COX-2 and lymphatic vessel density (LVD), tumor size, histological type, differentiation, lymph node metastasis, clinical recurrence and survival time of the patients.